France's Inventiva 2025 revenue halves on lower licensing income, net loss widens sharply

Inventiva SA

30/03/2026 21:23

Overview

France biopharma firm's 2025 revenue fell 51% to €4.5 mln, driven by lower licensing income

FY net loss widened to €354.1 mln, mainly due to increased G&A and financial expenses

Company completed U.S. public offering, raising $172.5 mln, expects cash runway until mid-Q1 2027

Outlook

Inventiva expects topline results from NATiV3 Phase 3 trial in Q4 2026

Company estimates cash runway until mid-Q1 2027

Inventiva preparing for potential commercialization of lanifibranor, if approved

Result Drivers

LICENSING INCOME DROP - Revenue fell mainly due to lower licensing income from CTTQ agreement

SHARE-BASED COMPENSATION - G&A expenses rose sharply due to share-based compensation from management and governance changes

PRE-COMMERCIALIZATION SPEND - Marketing and business development expenses increased due to preparation for potential commercialization of lanifibranor

Company press release: ID:nGNEc919r8

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
-EUR 1.90
FY Net Income
-EUR 354.14 mln
FY Operating Income
-EUR 141.01 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Inventiva SA is €13.04, about 171.6% above its March 30 closing price of €4.80

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)